B-intervention	0	12	Phototherapy
I-intervention	13	16	660
I-intervention	17	19	nm
O	20	23	for
O	24	27	the
O	28	38	prevention
O	39	41	of
B-condition	42	57	radiodermatitis
O	58	60	in
O	61	67	breast
O	68	74	cancer
O	75	83	patients
O	84	93	receiving
O	94	103	radiation
O	104	111	therapy
O	111	112	:
O	113	118	study
O	119	127	protocol
O	128	131	for
O	132	133	a
O	134	144	randomized
O	145	155	controlled
O	156	161	trial
O	161	162	.

O	163	169	Breast
O	170	179	neoplasms
O	180	183	are
O	184	187	the
O	188	194	second
O	195	199	most
O	200	206	common
O	207	211	type
O	212	214	of
O	215	221	cancer
O	222	231	worldwide
O	231	232	,
O	233	236	and
O	237	246	radiation
O	247	254	therapy
O	255	257	is
O	258	259	a
O	260	263	key
O	264	273	component
O	274	276	of
O	277	282	their
O	283	292	treatment
O	292	293	.

O	294	299	Acute
O	300	304	skin
O	305	314	reactions
O	315	318	are
O	319	322	one
O	323	325	of
O	326	329	the
O	330	334	most
O	335	341	common
O	342	346	side
O	347	354	effects
O	355	357	of
O	358	367	radiation
O	368	375	therapy
O	375	376	,
O	377	380	and
O	381	391	prevention
O	392	394	of
O	395	399	this
O	400	407	adverse
O	408	413	event
O	414	417	has
O	418	422	been
O	423	435	investigated
O	436	438	in
O	439	446	several
O	447	454	studies
O	454	455	.

O	456	463	However
O	463	464	,
O	465	466	a
O	467	477	clinically
O	478	488	applicable
O	488	489	,
O	490	502	preventative
O	503	512	treatment
O	513	520	remains
O	521	532	unavailable
O	532	533	.

O	534	536	It
O	537	540	has
O	541	545	been
O	546	558	demonstrated
O	559	563	that
O	564	575	application
O	576	578	of
O	579	580	a
O	581	584	low
O	584	585	-
O	585	590	power
O	591	596	laser
O	597	600	can
O	601	608	promote
O	609	615	tissue
O	616	622	repair
O	622	623	.

O	624	633	Therefore
O	633	634	,
O	635	638	the
O	639	642	aim
O	643	645	of
O	646	650	this
O	651	656	trial
O	657	659	is
O	660	662	to
O	663	671	evaluate
O	672	675	the
O	676	689	effectiveness
O	690	692	of
O	693	695	an
O	696	702	indium
O	703	710	gallium
O	711	719	aluminum
O	720	730	phosphorus
O	731	732	(
O	732	739	InGaAIP
O	739	740	)
O	741	746	laser
O	747	755	operated
O	756	758	at
O	759	762	660
O	763	765	nm
O	766	768	in
O	769	779	preventing
O	780	795	radiodermatitis
O	796	798	in
O	799	804	women
O	805	815	undergoing
O	816	824	adjuvant
O	825	837	radiotherapy
O	838	841	for
O	842	848	breast
O	849	855	cancer
O	855	856	.

O	857	861	This
O	862	864	is
O	865	866	a
O	867	870	two
O	870	871	-
O	871	874	arm
O	874	875	,
O	876	886	randomized
O	887	897	controlled
O	898	903	trial
O	903	904	.

O	905	906	A
O	907	912	total
O	913	915	of
B-total-participants	916	918	52
B-eligibility	919	927	patients
I-eligibility	928	938	undergoing
I-eligibility	939	951	radiotherapy
I-eligibility	952	955	for
I-eligibility	956	962	breast
I-eligibility	963	969	cancer
I-eligibility	970	971	(
I-eligibility	971	977	stages
I-eligibility	978	979	I
I-eligibility	980	982	to
I-eligibility	983	986	III
I-eligibility	986	987	)
O	988	992	will
O	993	995	be
O	996	1004	enrolled
O	1004	1005	.

O	1006	1014	Patients
O	1015	1019	will
O	1020	1022	be
O	1023	1031	randomly
O	1032	1040	assigned
O	1041	1043	to
O	1044	1046	an
O	1047	1059	intervention
O	1060	1065	group
O	1066	1068	to
O	1069	1076	receive
O	1077	1082	laser
O	1083	1090	therapy
O	1091	1092	(
O	1092	1093	n
O	1094	1095	=
B-intervention-participants	1096	1098	26
O	1098	1099	)
O	1100	1102	or
O	1103	1104	a
B-control	1105	1112	control
I-control	1113	1118	group
O	1119	1121	to
O	1122	1129	receive
O	1130	1131	a
O	1132	1139	placebo
O	1140	1141	(
O	1141	1142	n
O	1143	1144	=
B-control-participants	1145	1147	26
O	1147	1148	)
O	1148	1149	.

O	1150	1153	The
O	1154	1159	laser
O	1160	1162	or
O	1163	1170	placebo
O	1171	1175	will
O	1176	1178	be
O	1179	1186	applied
O	1187	1191	five
O	1192	1196	days
O	1197	1198	a
O	1199	1203	week
O	1203	1204	,
O	1205	1216	immediately
O	1217	1223	before
O	1224	1228	each
O	1229	1241	radiotherapy
O	1242	1249	session
O	1249	1250	.

O	1251	1255	Skin
O	1256	1265	reactions
O	1266	1270	will
O	1271	1275	then
O	1276	1278	be
O	1279	1285	graded
O	1286	1292	weekly
O	1293	1295	by
O	1296	1297	a
O	1298	1303	nurse
O	1303	1304	,
O	1305	1306	a
O	1307	1321	radiotherapist
O	1321	1322	,
O	1323	1326	and
O	1327	1329	an
O	1330	1340	oncologist
O	1341	1342	(
O	1342	1345	all
O	1346	1348	of
O	1349	1353	whom
O	1354	1358	will
O	1359	1361	be
O	1362	1369	blinded
O	1369	1370	)
O	1371	1376	using
O	1377	1380	the
O	1381	1387	Common
O	1388	1396	Toxicity
O	1397	1405	Criteria
O	1406	1407	(
O	1407	1410	CTC
O	1410	1411	)
O	1412	1421	developed
O	1422	1424	by
O	1425	1428	the
O	1429	1437	National
O	1438	1444	Cancer
O	1445	1454	Institute
O	1455	1458	and
O	1459	1462	the
O	1463	1468	Acute
O	1469	1478	Radiation
O	1479	1488	Morbidity
O	1489	1496	Scoring
O	1497	1505	Criteria
O	1506	1515	developed
O	1516	1518	by
O	1519	1522	the
O	1523	1532	Radiation
O	1533	1540	Therapy
O	1541	1549	Oncology
O	1550	1555	Group
O	1555	1556	.

O	1557	1565	Patients
O	1566	1570	will
O	1571	1575	also
O	1576	1582	answer
O	1583	1584	a
O	1585	1593	modified
O	1594	1600	visual
O	1601	1609	analogue
O	1610	1615	scale
O	1616	1619	for
O	1620	1624	pain
O	1625	1626	(
O	1626	1627	a
O	1628	1632	self
O	1632	1633	-
O	1633	1643	evaluation
O	1644	1657	questionnaire
O	1657	1658	)
O	1658	1659	.

O	1660	1667	Primary
O	1668	1671	and
O	1672	1681	secondary
O	1682	1690	outcomes
O	1691	1695	will
O	1696	1698	be
O	1699	1702	the
B-outcome-Measure	1703	1713	prevention
I-outcome-Measure	1714	1716	of
I-outcome-Measure	1717	1732	radiodermatitis
O	1733	1736	and
B-outcome-Measure	1737	1741	pain
I-outcome-Measure	1742	1751	secondary
I-outcome-Measure	1752	1754	to
I-outcome-Measure	1755	1770	radiodermatitis
O	1770	1771	,
O	1772	1784	respectively
O	1784	1785	.

O	1786	1789	The
O	1790	1795	ideal
O	1796	1800	tool
O	1801	1804	for
O	1805	1815	preventing
O	1816	1831	radiodermatitis
O	1832	1834	is
O	1835	1837	an
O	1838	1843	agent
O	1844	1848	that
O	1849	1857	mediates
O	1858	1861	DNA
O	1862	1868	repair
O	1869	1871	or
O	1872	1880	promotes
O	1881	1885	cell
O	1886	1899	proliferation
O	1899	1900	.

O	1901	1912	Application
O	1913	1915	of
O	1916	1917	a
O	1918	1921	low
O	1921	1922	-
O	1922	1927	power
O	1928	1933	laser
O	1934	1937	has
O	1938	1942	been
O	1943	1948	shown
O	1949	1951	to
B-outcome	1952	1959	promote
I-outcome	1960	1966	tissue
I-outcome	1967	1973	repair
I-outcome	1974	1976	by
I-outcome	1977	1985	reducing
I-outcome	1986	1998	inflammation
I-outcome	1999	2002	and
I-outcome	2003	2011	inducing
I-outcome	2012	2020	collagen
I-outcome	2021	2030	synthesis
O	2030	2031	.

O	2032	2040	Moreover
O	2040	2041	,
O	2042	2046	this
O	2047	2056	treatment
O	2057	2065	approach
O	2066	2069	has
O	2070	2073	not
O	2074	2078	been
O	2079	2089	associated
O	2090	2094	with
B-outcome	2095	2102	adverse
I-outcome	2103	2109	events
O	2110	2113	and
O	2114	2116	is
O	2117	2121	cost
O	2121	2122	-
O	2122	2131	effective
O	2131	2132	.

O	2133	2137	Thus
O	2137	2138	,
O	2139	2142	the
O	2143	2150	results
O	2151	2153	of
O	2154	2158	this
O	2159	2166	ongoing
O	2167	2172	trial
O	2173	2176	may
O	2177	2186	establish
O	2187	2194	whether
O	2195	2198	use
O	2199	2201	of
O	2202	2203	a
O	2204	2207	low
O	2207	2208	-
O	2208	2213	power
O	2214	2219	laser
O	2220	2230	represents
O	2231	2233	an
O	2234	2239	ideal
O	2240	2249	treatment
O	2250	2256	option
O	2257	2260	for
O	2261	2264	the
O	2265	2275	prevention
O	2276	2278	of
O	2279	2294	radiodermatitis
O	2294	2295	.

O	2296	2310	ClinicalTrials
O	2310	2311	.
O	2311	2314	gov
O	2315	2325	identifier
O	2325	2326	:
O	2327	2338	NCT02003599
O	2338	2339	.

O	2340	2350	Registered
O	2351	2353	on
O	2354	2355	2
O	2356	2364	December
O	2365	2369	2013
O	2369	2370	.
